By eliminating the need for breast compression, the KBCT yields high-quality images containing all the information necessary to complete a diagnosis
MOUNTAIN VIEW, California, Oct. 18, 2016 /PRNewswire/ -- Based on its recent analysis of the breast imaging market, Frost & Sullivan recognizes Koning Corporation with the 2016 North America Frost & Sullivan Award for New Product Innovation. With its Food and Drug Administration (FDA) approval in 2015, the Koning Breast Computed Tomography (KBCT) became the first dedicated breast CT imaging system in North America. It is a unique modality that provides 3-D isotropic multi-planar images of the breast without compression and with high dosage efficiency. This technology enables the precise detection, assessment, and quantification of abnormalities in breasts.
Logo - http://photos.prnewswire.com/prnh/20161017/429302LOGO
The KBCT represents one of the most significant innovations in the breast imaging space over the last few years, as it seeks to address the limitations of both mammography and digital breast tomosynthesis (DBT). It generates images that allow clinicians to co-registrate disease size and location on a 3-D plane, as opposed to extrapolating using DBT reconstruction algorithms.
Recognizing that the adherence of women to screening programs has been declining, Koning focused on enhancing patient comfort. The KBCT is designed to image the breast without compression, using a radiation dose comparable to diagnostic mammography. These images aid in effective cancer detection and diagnosis, especially among women with dense breast tissue who are susceptible to false negatives.
"Apart from its diagnostic capabilities, dose efficiency, and patient comfort benefits, KBCT has the ability to serve as an interventional modality as part of the diagnostic scanning workflow," said Frost & Sullivan Senior Research Analyst Tanvir Jaikishen. "This is not possible with mammography, which requires additional equipment for stereotactic image-guided biopsies."
KBCT images have more detail and diagnostic insights than the current standards. Being a compression-free imaging procedure, it boasts an imaging protocol time of approximately 10 seconds per breast. This, in turn, improves workflow efficiencies. These differentiators have allowed the company to price the product at a premium.
KBCT's cost, quality, and efficiency advantages are perfectly aligned with the healthcare systems' new priorities of cost optimization, superior care, and patient outcomes. The KBCT achieves these goals by combining an advanced diagnostic function and a state-of-the-art biopsy function.
In addition to the FDA, the KBCT received approval from China FDA, the Conformité Européenne (CE) for the European Union, and a series of other regulatory approvals including those for the Australian and Canadian markets. As it aims to expand globally, the company has applied for regulatory approvals in Asia-Pacific and South American countries, notably Japan, Singapore, Malaysia, the Philippines, Brazil, and Mexico.
"The enthusiastic market acceptance of the KBCT is a clear testament to its excellent reliability and effectiveness," noted Jaikishen. "It has demonstrably proved that it has comparable and, in some cases, better efficacy than conventional modalities."
Koning's KBCT is uniquely positioned for sustained success because it addresses the core issues of quality, functionality and reliability. For its outstanding ability to develop innovative products to address unmet customer requirements, Frost & Sullivan is pleased to present Koning with the 2016 North America Frost & Sullivan Award for New Product Innovation.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the higher ROI it offers customers, which in turn improves customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Koning Corporation
Create a revolution in medical imaging through our advanced Computed Tomography technology. We believe our Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention and treatment in numerous areas of the body. Our hope is to be able to improve survival rates and outcomes for millions of patients. We believe that the power, versatility and lower cost of Koning Breast CT will serve as a viable substitute for many traditional imaging applications.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact:
Chiara Carella P: +44 (0) 207.343.8314 F: 210.348.1003 E: [email protected]
Advertisement
MOUNTAIN VIEW, California, Oct. 18, 2016 /PRNewswire/ -- Based on its recent analysis of the breast imaging market, Frost & Sullivan recognizes Koning Corporation with the 2016 North America Frost & Sullivan Award for New Product Innovation. With its Food and Drug Administration (FDA) approval in 2015, the Koning Breast Computed Tomography (KBCT) became the first dedicated breast CT imaging system in North America. It is a unique modality that provides 3-D isotropic multi-planar images of the breast without compression and with high dosage efficiency. This technology enables the precise detection, assessment, and quantification of abnormalities in breasts.
Advertisement
Logo - http://photos.prnewswire.com/prnh/20161017/429302LOGO
The KBCT represents one of the most significant innovations in the breast imaging space over the last few years, as it seeks to address the limitations of both mammography and digital breast tomosynthesis (DBT). It generates images that allow clinicians to co-registrate disease size and location on a 3-D plane, as opposed to extrapolating using DBT reconstruction algorithms.
Recognizing that the adherence of women to screening programs has been declining, Koning focused on enhancing patient comfort. The KBCT is designed to image the breast without compression, using a radiation dose comparable to diagnostic mammography. These images aid in effective cancer detection and diagnosis, especially among women with dense breast tissue who are susceptible to false negatives.
"Apart from its diagnostic capabilities, dose efficiency, and patient comfort benefits, KBCT has the ability to serve as an interventional modality as part of the diagnostic scanning workflow," said Frost & Sullivan Senior Research Analyst Tanvir Jaikishen. "This is not possible with mammography, which requires additional equipment for stereotactic image-guided biopsies."
KBCT images have more detail and diagnostic insights than the current standards. Being a compression-free imaging procedure, it boasts an imaging protocol time of approximately 10 seconds per breast. This, in turn, improves workflow efficiencies. These differentiators have allowed the company to price the product at a premium.
KBCT's cost, quality, and efficiency advantages are perfectly aligned with the healthcare systems' new priorities of cost optimization, superior care, and patient outcomes. The KBCT achieves these goals by combining an advanced diagnostic function and a state-of-the-art biopsy function.
In addition to the FDA, the KBCT received approval from China FDA, the Conformité Européenne (CE) for the European Union, and a series of other regulatory approvals including those for the Australian and Canadian markets. As it aims to expand globally, the company has applied for regulatory approvals in Asia-Pacific and South American countries, notably Japan, Singapore, Malaysia, the Philippines, Brazil, and Mexico.
"The enthusiastic market acceptance of the KBCT is a clear testament to its excellent reliability and effectiveness," noted Jaikishen. "It has demonstrably proved that it has comparable and, in some cases, better efficacy than conventional modalities."
Koning's KBCT is uniquely positioned for sustained success because it addresses the core issues of quality, functionality and reliability. For its outstanding ability to develop innovative products to address unmet customer requirements, Frost & Sullivan is pleased to present Koning with the 2016 North America Frost & Sullivan Award for New Product Innovation.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the higher ROI it offers customers, which in turn improves customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Koning Corporation
Create a revolution in medical imaging through our advanced Computed Tomography technology. We believe our Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention and treatment in numerous areas of the body. Our hope is to be able to improve survival rates and outcomes for millions of patients. We believe that the power, versatility and lower cost of Koning Breast CT will serve as a viable substitute for many traditional imaging applications.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact:
Chiara Carella P: +44 (0) 207.343.8314 F: 210.348.1003 E: [email protected]
